Compare GSK plc (GSK) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Sezzle Inc — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Sezzle Inc trades at $128.18 (market cap $3.95B). The key difference: GSK plc is far larger — about 23.3× Sezzle Inc's market cap, and GSK plc pays a 3.9% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Sezzle Inc for 15 Days on average.
| GSK | SEZL | |
|---|---|---|
Market Cap | $91.88B | $3.95B |
Volume | 7,730,529 | 550,075 |
Sector | Health | Financials |
52-Week High | $61.18 | $188.55 |
52-Week Low | $43.24 | $50.97 |
Typical Hold Time | 93 Days | 15 Days |
Enterprise Value | $111.88B | $3.99B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SEZL stock is trading at $128.64, up 12.99% in the past 24 hours, showing strong momentum with a bullish technical signal. The company demonstrates exceptional profitability with 72.36% gross margins and 30.35% net income margins, while recent earnings have consistently beaten expectations. Analyst consensus remains strongly positive with a $168 price target representing significant upside potential from current levels.
SEZL presents a compelling growth opportunity with robust financial metrics and strong analyst support, though investors should monitor competitive pressures in the BNPL sector and the stock's current technical overbought conditions. The company's expanding product portfolio and subscriber growth provide fundamental support for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
